Boehringer adds to cancer drug pipeline with deal for startup Nerio

Boehringer Ingelheim is investing again in immuno-oncology, announcing Monday a deal to acquire the San Diego-based biotechnology startup Nerio Therapeutics and its slate of preclinical drug candidates.